Literature DB >> 22180282

[Management of digital ulcers in patients with systemic sclerosis].

G Riemekasten1, U Hoffmann, C Sunderkötter, N Weiss, A Kuhn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180282     DOI: 10.1055/s-0031-1298798

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


× No keyword cloud information.
  6 in total

Review 1.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

2.  [Systemic scleroderma].

Authors:  N Hunzelmann
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

3.  [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].

Authors:  G Riemekasten; S Beissert; J H W Distler; A Kreuter; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

Review 4.  [Current treatment of systemic scleroderma].

Authors:  Nicolas Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

5.  Immune Modulation to Enhance Bone Healing-A New Concept to Induce Bone Using Prostacyclin to Locally Modulate Immunity.

Authors:  Sebastian Wendler; Claudia Schlundt; Christian H Bucher; Jan Birkigt; Christian J Schipp; Hans-Dieter Volk; Georg N Duda; Katharina Schmidt-Bleek
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

6.  [Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany].

Authors:  A Juche; E Siegert; U Mueller-Ladner; G Riemekasten; C Günther; I Kötter; J Henes; N Blank; R E Voll; J Ehrchen; M Schmalzing; L Susok; T Schmeiser; C Sunderkoetter; J Distler; M Worm; A Kreuter; O N Horváth; M P Schön; P Korsten; G Zeidler; C Pfeiffer; T Krieg; N Hunzelmann; P Moinzadeh
Journal:  Z Rheumatol       Date:  2020-12       Impact factor: 1.372

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.